cyrilzakka/clinical-trials huggingface dataset:
Modulating Prefrontal Circuits Underlying Behavioral Flexibility in OCD: A TMS Study

This study investigates whether slow-frequency repetitive transcranial magnetic stimulation targeting frontal pole can acutely modulate brain circuits which show abnormal functioning during behavioral flexibility in obsessive-compulsive disorder, as well as performance on a behavioral task.


Eligibility Criteria:
Inclusion Criteria: OCD group

* current primary diagnosis of obsessive-compulsive disorder and Yale-Brown Obsessive Compulsive Scale total score ≥ 16;
* 18-55 years of age;
* ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent;
* either no use of psychiatric medication or stable psychiatric medication use for 6 weeks prior to study entry, limited to use of serotonin reuptake inhibitors and PRN use of benzodiazepines (other psychiatric medication use excluded), and
* right-handed.

Inclusion Criteria: Healthy Control group

* 18-55 years of age;
* ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent;
* right-handed.

Exclusion Criteria: OCD group

* active problematic substance use;
* lifetime psychosis or bipolar mood disorder or OCD beliefs of delusional nature;
* clinically significant hoarding symptoms;
* active suicidal or homicidal ideation;
* significant neurological disease or intracranial pathology;
* use of medications which increase risk for seizures during TMS;
* significant or unstable medical disorders or contraindication to TMS or MRI scan.

Exclusion Criteria: Healthy Control group

* current psychiatric diagnosis;
* lifetime psychosis, bipolar mood disorder, or OCD;
* active suicidal or homicidal ideation;
* significant neurological disease or intracranial pathology;
* use of psychiatric medications;
* use of medications which increase risk for seizures during TMS;
* significant or unstable medical disorders or contraindication to TMS or MRI scan.
Radial Extracorporeal Shock Wave Therapy Versus High Power Pain Threshold Ultrasound Therapy in Supraspinatus Tendinitis

Extra corporeal shock wave therapy is a treatment method in which high-amplitude sound waves are focused on the targeted body tissue Recently, Extra corporeal shock wave therapy has been proposed as an alternative treatment in patients not responding to pharmaceutical treatment.High power pain threshold ultrasound is the use of therapeutic ultrasound in a continuous mode; with the probe placed directly on affected area (supraspinatus tendon)

Shock wave therapy is an effective method of dissolving calcification and stimulating tissue healing. Extra corporeal shock wave therapy is a treatment method in which high-amplitude sound waves are focused on the targeted body tissue Recently, Extra corporeal shock wave therapy has been proposed as an alternative treatment in patients not responding to pharmaceutical treatment.US have been widely used for more than 40 years in the treatment of musculoskeletal disorders such as tendinitis, tenosynovitis, epicondylitis, bursitis and osteoarthritis. High power pain threshold ultrasound is the use of therapeutic ultrasound in a continuous mode; with the probe placed directly on affected area (supraspinatus tendon) "the intensity of ultrasound is first increased to the threshold pain level (to 1.5 W/cm) and then reduced to one half of that intensity. It was kept at that level for 4 to 5 seconds and then reduced to the half-intensity level for another 15 seconds .

Eligibility Criteria:
Inclusion Criteria:

* Patients' age ranges from 30 to 50 years old.
* Patients are males and females.
* BMI of all subjects were \<30 Kg/m2.
* Patients will be diagnosed as supraspinatus tendinitis.
* All patients are medically stable.
* All patients should be conscious and ambulant.
* Patients don't have any nervous system problems
* Patients don't have shoulder disorder other than tendenities
* Patients that didn't undergo any surgery in shoulder joint

Exclusion Criteria:

* • Patients who received intra articular injection from duration less than 3 months.

  * Patients with supraspinatus tendonitis secondary to trauma.
  * Patients with metal implants.
  * Patient who had malignancy in the affected area.
  * Patient with acute infection in the treated area.
  * Diabetic patients
  * Bone infection
  * Shoulder instability
  * Epilepsy
  * Coagulation diseases
  * Rheumatological diseases (rheumatoid arthritis and gouty arthritis)
Xbox Kinect, Sleep Quality, Anxiety and Functional Capacity in Older Adults

The present study aims to examine the effects of Xbox Kinect exercise training program on the sleep quality, anxiety and functional capacity in older adults. Older adults were randomized into two groups. The XBOX group performed exercise with Xbox Kinect during 60 min, three times/week for 6 weeks. The CONTROL group did not exercise. Pittsburgh Sleep Quality Index was used to evaluate sleep quality, anxiety symptoms by the State-Trait Anxiety Inventory, and the functional capacity was analyzed using following tests: Chair Stand Test, 8-Foot Up and Go Test, and 6-min Walk Test.


Eligibility Criteria:
Inclusion Criteria:

1. ability to perform exercises with Xbox Kinect and/or physical/functional tests and to answer the questionnaires;
2. score ≥ 24 on the Mini-Mental State Examination

Exclusion Criteria:

(a) using psychiatric drugs or beta-blockers;

1. functional limitations
2. exercise regularly

(e) smoking (b) previous experience with Xbox Kinect games.
Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes

The study is a 2 phase double blind randomized placebo control trial. The objective is to asses the metabolic and therapeutic effects of American Ginseng (Panax quinquefolius L.) extract and Korean Red Ginseng (steamed Panax C.A. Meyer) extract in the management of type 2 diabetes in a 12 week period. One Hundred and twenty subjects with type 2 diabetes (hyperglycemia key inclusion criteria: HbAlc≥6.5% - ≤ 8.1% ) will participate in the study (36 men and 36 post-menopausal women).


Eligibility Criteria:
Inclusion Criteria:

* presence of type 2 diabetes (at least 1 year) as defined by A1c between ≥6.5% and ≤8.1%, at recruitment,
* treatment with diet or oral hypoglycemic medication be unchanged starting at least 2 months prior to the beginning of the study (at recruitment, week -8)
* between the age of 40 and 75 years
* systolic blood pressure \<140 and diastolic blood pressure \<90
* clinically euthyroid (measuring T3 and T4)
* normal renal and liver functions
* post-menopausal or non-pregnant women (Post-menopausal includes: those females with more than a year of cessation of menstruation)
* a negative result on a pregnancy test administered at screening
* subjects taking an effective form of birth control (example: condom, abstinence, etc.)
* willing to comply with the study protocol and sign a consent form

Exclusion Criteria:

* individuals with bleeding disorders
* individuals with allergies to nitroglycerin
* planned surgery, pregnancy or breastfeeding
* taking insulin; clinically significant diabetes complications (retinopathy, nephropathy, or neuropathy); serum triglycerides ≥ 4.5 mmol/L
* increased A1c level of more than 2% from baseline during the study
* history of angina or heart attack
* use of ginseng or any natural health products with glucose modulating and/or anti-platelet activity within 2 months
* BMI \> 35 kg/m2 including a weight fluctuation of + 2kg during treatment periods
* smoke cigarettes; alcohol intake \> 2 drinks/day
* the presence of any conditions which, in the opinion of the investigator, might jeopardize the health and safety of the subject or study personnel or adversely affect the study results, if the subject participated in the study
* Subjects taking Warfarin or Coumadin, prescription NSAIDs, chronic use of high-dose (\>81mg) non-prescription NSAIDs, or selective serotonin reuptake inhibitors and monoamine oxidase inhibitors, or sympathomimetics or medications affecting nitric oxide levels, or any known or suspected sensitivity to any of the ingredients in the test product or placebo cannot participate in the study.
Grade 2 Chondrosarcoma Treated by Intralesional Curettage: Follow-up vs Resection

The goal of this observational study is to assess the oncological outcomes in patients diagnosed with grade 2 chondrosarcoma, treated with intralesional curettage, stratified into two cohorts: those subjected to follow up monitoring and those who have undergone subsequent surgical intervention.

Large resection of the tumor is considered the treatment of choice in patients affected by grade 2 chondrosarcoma. Nonetheless, a preoperative diagnosis of a lower grade lesion (ChS grade 1) is not infrequent, thus making these patients treated with intralesional curettage. Intralesional curettage is a type of surgery in which the pathological component is removed from the affected bone and the resulting bone defects can be filled with bone substitutes or bone cement. Bone cortexes are left in place like a shell.

The results of this study could contribute to find the right therapeutic pathway in patients affected by grade 2 chondrosarcoma treated with intralesional curettage, in particular in patients who underwent further surgery (bone resection) or follow-up. Since outcome data are scarce in the literature, the results of this study could be used to assess the feasibility of a randomized controlled trial with the correct sample size.

It is an explorative, spontaneous, non-profit, retrospective, observational study.

It involves the pseudonymous data collection of all patients matching inclusion criteria. The data recorded in this study are extracted from the medical records of patients who regularly seek care from the medical unit during their routine clinical visits. Following a meticulous collection of patients' baseline data, the two therapeutic options (clinical monitoring or bone resection) in patients affected by grade 2 chondrosarcoma treated with intralesional curettage will be compared.

Data related to demographics, histologic and treatment data will be collected. Oncologic follow-up data will be also collected. In particular, data related to local recurrences, distant metastasis and survival will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of grade 2 chondrosarcoma of the appendiceal skeleton in the definitive specimen;
* Patients treated with intralesional curettage surgery;
* Patients aged \>=18 years;
* Patients who were treated between 01/01/2008 and 31/12/2020.

Exclusion Criteria:

* Patients diagnosed with grade 1 or 3 chondrosarcoma on the histological diagnosis of the operative specimen.
* Patients undergoing wide resection as the primary treatment.
* Patients with less than 12 months follow-up.
Alveolar Ridge Changes Post Tooth Extraction With Socket Shield Without Immediate Implant Placement"

This study aimed to evaluate the dimensional changes in the alveolar ridge after tooth extraction using the socket shield technique without immediate implant placement. The changes using CBCT were assessed, focusing on the preservation of the ridge for delayed implant placement. This research could help improve dental implant outcomes by preserving bone and soft tissue structures."

"In this clinical trial, the dimensional changes in the alveolar ridge following tooth extraction were investigated using the socket shield technique. The socket shield technique involved partial retention of the root structure to preserve the surrounding bone and soft tissues. No immediate implant placement was performed, and the ridge changes were assessed at multiple time points through CBCT scans. The study included a specified sample size, and participants underwent a follow-up of 6 months after socket shield preparation. This research aimed to provide insights into how well the socket shield technique preserves ridge dimensions over time, potentially optimizing future implant stability."

Eligibility Criteria:
Inclusion Criteria:

* Non-restorable teeth in the esthetic region.
* The buccal periodontal tissues were intact.
* Maintaining oral hygiene.

Exclusion Criteria:

* The usual limitations for oral surgery.
* Tooth having a vertical fracture of the root on the facial aspect.
* Tooth having horizontal fracture of the root extending below the level of the bone.
* Caries on the root segment to be maintained.
* Mobility of the tooth.
* Bruxism.
Arterial Tone Influence on Cardiac Output Measured by PRAM

This study evaluates the role of arterial tone in the accuracy of cardiac output (CO) measurement by Pressure Recording Analytical Method (PRAM). Patients receiving noradrenaline who need for clinical reason to change the noradrenaline dose will be enrolled. We use echocardiography as reference method of CO measurement.

Pressure Recording Analytical Method (PRAM) is an arterial pulse contour analysis method for CO measurement. As it is an uncalibrated method, one possible reason for its inaccuracy is rapid changes in arterial tone.

Eligibility Criteria:
Inclusion Criteria:

* invasive blood pressure monitoring on site
* need to start or change the dose of noradrenaline infusion for clinical reason

Exclusion Criteria:

* age \<18
* arrhythmia
* severe valvular insufficiency
* pregnancy
* low quality arterial signal
A New Psychotherapy Intervention for Older Cancer Patients

This study is being done to see if a new psychotherapy intervention called Cancer and Aging: Reflections for Elders (CARE) can effectively treat depression and distress in older cancer patients. CARE is a 5-session intervention that takes place over the phone. This study will compare CARE with the Social Work and Supportive Counseling (SWSC) intervention, which also takes place over the phone. SWSC is a standard psychotherapeutic intervention that has been shown to be a supportive and effective form of treatment for distress for patients with cancer. The researchers will look at which intervention is more effective in treating depression and distress in participants.


Eligibility Criteria:
Inclusion Criteria:

* As per self-report or medical record, ≥ 70 years of age
* As per self-report or medical record, has a diagnosis of cancer
* As per self-report or medical record, receiving active treatment (e.g., radiation, chemotherapy, hormone); OR received active treatment in the past 6 months (N/A for training case participants); OR are currently on active surveillance with follow-ups at least approximately every 6 months
* Received a HADS-D score of ≥ 6 or HADS-A score of ≥ 6 or a score of ≥ 4 on the distress thermometer. (N/A for training case participants)
* Received a Karnofsky Performance Rating Scale (KPRS) score of ≥ 60 (N/A for training case participants)
* Received a Blessed Orientation-Memory-Concentration Scale (BOMC) score of ≤ 11 (N/A for training case participants)
* Fluent in English, as per self-reported fluency of "well" or "very well"\*

Exclusion Criteria:

* As per self-report, currently taking antidepressant medication for \< 3 months
* As per self-report, currently receiving hospice care
* In the judgment of the consenting professional is unable to provide informed consent and complete study sessions and assessment
* As per self-report or as documented in the medical record, current untreated (e.g., no medication, no therapy) major psychotic disorder (schizotypal personality disorder, schizophreniform disorder, schizoaffective disorder). Patients diagnosed with a major psychiatric disorder will be reviewed by the study PI to determine eligibility prior to consent.

  * Language verification: Prior to enrollment, patients will be asked the following two questions by research staff to verify English fluency necessary for participation in the study:

    1. How well do you speak English? (must respond "Well" or "Very well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
    2. What is your preferred language for healthcare? (must respond English)
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with irinotecan may kill more tumors cells.

PURPOSE: This phase II trial is studying the side effects of bevacizumab and how well giving bevacizumab together with irinotecan works in treating patients with recurrent or refractory gliomas.

OBJECTIVES:

Primary

* Determine the safety of bevacizumab and irinotecan hydrochloride in patients with recurrent or refractory grade 3 or 4 malignant gliomas.

Secondary

* Determine the activity of this regimen, in terms of progression-free survival, in these patients.

OUTLINE: Patients receive bevacizumab and irinotecan hydrochloride every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 68 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed primary grade 3 or 4 malignant glioma of 1 of the following types:

  * Glioblastoma multiforme
  * Gliosarcoma
  * Anaplastic astrocytoma
  * Anaplastic oligodendroglioma
* Patients with recurrent disease whose original diagnostic pathology confirmed malignant glioma will not need re-biopsy
* Measurable recurrent or residual primary disease on contrast-enhanced MRI or CT scan
* Failed ≥ 1 prior chemotherapy regimen (with or without radiotherapy)

PATIENT CHARACTERISTICS:

* Karnofsky performance status 60-100%
* Hematocrit \> 29%
* Absolute neutrophil count \> 1,500/mm\^3
* Platelets \> 125,000/mm\^3
* Serum SGOT and bilirubin \< 1.5 times upper limit of normal
* Creatinine \< 1.5 mg/dL
* Urine protein:creatinine ratio ≤ 1.0
* Blood pressure ≤ 150/100 mmHg
* No unstable angina
* No New York Heart Association class II or greater congestive heart failure
* No myocardial infarction within the past 6 months
* No stroke within the past 6 months
* No clinically significant peripheral vascular disease
* No evidence of bleeding diathesis or coagulopathy
* No significant traumatic injury within the past 28 days

PRIOR CONCURRENT THERAPY:

* At least 4 weeks must have elapsed since prior chemotherapy or radiotherapy unless there is unequivocal evidence of tumor progression
* At least 6 weeks since prior surgical resection
* No previous major surgical procedures or open biopsies within 28 days prior to study entry
* No previous minor surgical procedures, fine needle aspirations, or core biopsies within 7 days prior to study entry
* No anticipated need for major surgical procedures during the course of the study
* No concurrent aspirin, non-steroidal anti-inflammatory drugs, or clopidogrel
A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

The purpose of this study is to develop taste profiles of iberdomide and mezigdomide drug substances and oral formulation prototypes in order to develop a pediatric oral form of iberdomide and mezigdomide.


Eligibility Criteria:
Inclusion Criteria:

* Participant is qualified based on training and experience.
* Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling.
* Participant is qualified based on training and experience.
* Senopsys LLC will provide all participants.
* Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling.

Exclusion Criteria:

* Participant has any history of any illness, medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the investigator, might confound the results of the study or places the participant at unacceptable risk if he or she were to participate in the study.
* Participant has a known hypersensitivity to mezigdomide, iberdomide, thalidomide, lenalidomide, or pomalidomide.
* Participant is a female that is pregnant, breastfeeding, or is a women of childbearing potential (WOCBP).
DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis

Physical activity is considered essential for optimal health, development, socialization and well-being of children. However patients with end-stage renal disease (ESRD) are often restricted from participation in exercise activities. This is especially true for children on hemodialysis (HD). As a consequence their exercise capacity is reduced, both before, but most impressively after HD. In a nationwide randomized, multi-center design this study aims to proof the influence of an individualised endurance training program by bicycle ergometer performed during dialysis on the efficacy of HD, measured as single pool Kt/V. Secondary goals are to enhance physical performance, physical and mental well-being, and to improve measurable blood and treatment parameters (e.g. haemoglobin level, amount of medication). A positive impact of physical activity was observed in adults on HD, although most studies did not address this issue in a randomised protocol. Despite this beneficial evidence in adults, sport is still not integrated as part of standard care in patients on maintenance HD. The study protocol, developed in close collaboration with the German Sport University Cologne, differs substantially from previously published reports as it uses bicycle ergometer training in an upright position outside the dialysis couch and adapts the intensity of intervention to the patient's capabilities. Based on the expected results the investigators will develop an individualised training program to be integrated in the standard care of (pediatric) patients on maintenance HD.


Eligibility Criteria:
Inclusion Criteria:

* End stage renal disease with need of renal replacement therapy
* children and adolescents aged ≥6 to ≤19 years
* maintenance hemodialysis for at least 3 months
* Stable and appropriate dialysis condition in the last 4 weeks before inclusion to the study (basically stable blood and dialysate flow rate and same dialyser)
* single pool Kt/V according to Dialysestandard 2006 \> 1.2
* Informed consent

Exclusion Criteria:

* Participation in another interventional clinical trial
* severe primary neurologic, orthopaedic or cardiac disease, or secondary disease known as a contraindication for endurance training
* uncontrolled hyper- or hypotension, or cardiac disease
* Recurrent uncontrolled epileptic seizures
* dialysis shunt at the lower limbs
* pregnancy
* already planned medical intervention, for example living donor kidney transplantation or any other surgery, within the first period of the trial which will cause cancelation of more then 3 training units in a row
* Subjects who are in dependency to the sponsor or the PI of the trial, or confined to an institution on judicial or official behalf